Experimental combo for advanced colon cancer shows early promise but trial halted
NCT ID NCT04166383
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of two drugs, VB-111 and nivolumab, in 14 adults with colorectal cancer that had spread to the liver. The goal was to see if the treatment was safe and could shrink tumors. The trial was terminated early, but researchers collected data on side effects and tumor response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER WITH HEPATIC METASTASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can delivering cancer drug directly to the liver shrink tumors?
- A simple blood draw could spot colorectal cancer early
- Blood biomarkers could replace invasive biopsies for colorectal cancer monitoring
- Peer power: could community education boost cancer screening?
- Can a Cancer-Fighting virus shrink tumors when chemo fails?
- AI eye for colonoscopy: could software catch what doctors miss?